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Background: saliva is useful to assess health or disease states. Recently, proteomic technologies have
allowed rapid progress in saliva analysis.
Highlight: (1) saliva contains three main types of extracellular vesicles; (2) the vesicles are exosomes,
microvesicles, and apoptotic bodies; (3) proteome is analyzed in saliva, salivary exosomes, and salivary
microvesicles; (4) membrane transporters are in saliva, and salivary exosomes and/or microvesicles;
(5) biomarker discovery in exosomes and microvesicles of saliva is progressing.
Conclusion: membrane transporters such as aquaporin, ion channels, carriers in saliva, and salivary
exosomes or microvesicles, might be valuable biomarkers of systemic or oral health.
& 2014 Japanese Association for Oral Biology. Published by Elsevier B.V.
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1. Introduction
Saliva is an important body ﬂuid that reﬂects systemic and
oral conditions. Because saliva sampling is non-invasive, painless,
stress-free, and relatively simple when compared with blood
collection, saliva is a useful tool for assessing health or disease
states. Because of these signiﬁcant advantages, the discovery of
salivary biomarkers associated with health and diseases is desirable.
Saliva is majorly (99%) made up of water, and the other 1%
is composed of electrolytes, proteins, peptides, polynucleotides, hor
mones, enzymes, cytokines, antibodies, and other substances [1].
In recent years, proteomic technologies have rapidly progressed the
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analysis of saliva, conﬁrming that 20–30% of the salivary proteome
overlaps with the plasma proteome [2,3].
In body ﬂuids, such as saliva, there are three main classes of
extracellular vesicles: exosomes, microvesicles, and apoptotic
bodies [4–6]. In contrast to microvesicles, which are generated
by shedding from the plasma membrane, exosomes are derived
from multivesicular bodies that are components of the endocytic
pathway [7]. Biomarker discovery is now progressing with regard
to analysis of salivary exosomes and microvesicles.
2. Traditional biomarkers
Salivary unbound steroids, such as cortisol, estradiol, and
testosterone, are correlated with their free-form serum concentra-
tions [8], while conjugated steroids, such as dehydroepiandroster-
one sulfate and estriol-3-sulfate, are present in saliva at only 1% of
their unbound serum concentrations. To evaluate serum hormone
status, salivary unbound hormone levels are measured.
2.1. Cortisol
Salivary cortisol appears to be independent of transport pro-
teins, such as albumin and cortisol-binding globulin, and therefore
reﬂects the bioactive, free molecule [9]. Salivary cortisol levels are
used to assess Cushing's syndrome [10], adrenal insufﬁciency [9],
exercise-related stress [11], and mental stress [12].
2.2. Aldosterone
Aldosterone is lipid-soluble and enters saliva by passive diffu-
sion through cells of the salivary gland; thus, the concentration in
saliva does not depend on ﬂow rate, giving a clinically useful index
of unbound plasma levels [13]. Salivary aldosterone is used to
assess primary aldosterone associated with cardiac ﬁbrosis, ven-
tricular and vascular remodeling, and increased cardiovascular
morbidity and mortality [13,14].
2.3. Insulin
Salivary insulin concentration is positively correlated with
plasma free insulin levels [15]. After glucose loading, plasma and
salivary insulin can be correlated using an immunoreactive mea-
suring method [16].
2.4. Adiponectin
Adiponectin is released from adipose tissue into blood and is
abundantly present in healthy human plasma at 5–30 μg/mL [17].
Plasma adiponectin levels are inversely associated with visceral fat
accumulation [18]. Adiponectin has anti-diabetic, anti-hyperten-
sive, anti-inﬂammatory and anti-oncogenic functions. Hypoadipo-
nectinemia induced by visceral fat accumulation is a strong risk
factor for metabolic and cardiovascular disease, as well as some
types of cancer.
Salivary adiponectin levels range from 0.37–6.42 ng/mL [19].
There is a signiﬁcant correlation between plasma and salivary
adiponectin levels. This suggests that salivary adiponectin may be
a marker of increased risk of non-insulin-dependent diabetes
mellitus or cardiovascular disease.
3. Salivary proteome and diagnosis
Proteomics is the large-scale study of proteins, and their
structure and function. Although proteins are products of genes,
multiple distinct protein isoforms can be created from a single
gene. Because proteins are also susceptible to posttranslational
modiﬁcations, proteomics more accurately reﬂect cellular pro-
cesses. Secreted proteins released from diseased cells contain
important biological information. Comparison of protein patterns
in biological ﬂuids between healthy individuals and patients with
a given disease can be used to discover biological disease markers.
The major analytical strategies in proteomics are ﬁngerprint
analysis and shotgun analysis.
Fingerprint protein analysis refers to bottom-down proteomics
[20]. Proteins are separated ﬁrst by two-dimensional gel electro-
phoresis and are then visualized by staining. To identify proteins,
spots are excised and digested with trypsin. The resulting peptides
are extracted and subjected to liquid chromatography–tandem mass
spectrometry (LC–MS/MS) or matrix-assisted laser desorption/ioni-
zation-time of ﬂight (MALDI-MS/MS) [21] for identiﬁcation.
Shotgun protein analysis refers to bottom-up proteomics
[22,23]. Proteins are ﬁrst cleaved by enzymatic or chemical
methods, and are then subjected to LC–MS/MS, MALDI-MS/MS or
ESI–MS/MS [24] to recover peptides.
Using ﬁngerprint analysis, 2340 proteins were identiﬁed in
whole human saliva, and approximately 20% of total salivary
proteins are seen in plasma [2]. On the other hand, 1939 proteins
were identiﬁed in human saliva by the shotgun method and 27% of
these have been observed in plasma [3].
Proteomic technologies are currently being used to discover
disease biomarkers, particularly for oral cancer [25,26], lung
disease [27], Sjögren's syndrome [28,29], and gingivitis [30].
4. Salivary exosomes and diagnosis
Exosomes are small membrane vesicles (40–100 nm in dia-
meter) of endocytic origin that are secreted by most cell types
upon fusion of multivesicular bodies with the plasma membrane
[7]. Exosomes have been identiﬁed in body ﬂuids, such as breast
milk, blood, urine, semen, amniotic ﬂuid, ascites ﬂuid, and saliva
[4]. Exosomes participate in intercellular communication [31–33],
immune regulatory functions [34], transport of morphogens and
RNA [35–37], and tumor metastasis [38].
Gonzalez-Begne et al. cataloged 491 proteins in the exosome
fraction of human parotid saliva using the shotgun approach [39].
Forty-three percent of 491 proteins were of cytosolic origin, 26%
were integral plasma membrane proteins, and 13% were asso-
ciated/peripheral plasma membrane proteins. Integral plasma
membrane proteins were annotated according to their function:
pumps (2%); channel protein (5%); and solute carriers (14%).
Ogawa et al. identiﬁed two types of exosome in whole human
saliva; exosome І (mean diameter: 84 nm) and exosome ІІ (mean
diameter: 40 nm) [40]. Exosomes І and ІІ contain numerous
plasma membrane proteins: single-pass transmembrane proteins,
such as type І and type ІІ membrane proteins; tetraspanins;
pentaspans; the six-pass membrane protein, aquaporin-5; and
seven-pass membrane proteins. Alpha-amylase (about 20% of
salivary proteins) and proline-rich proteins (about 40% of salivary
proteins) were also detected in exosome І and exosome ІІ.
Exosomal proteome studies are listed in Table 1.
Salivary exosomes have been shown to be useful in detecting
diseases, such as Sjögren's syndrome [41], as well as head and
neck cancer [38].
5. Salivary microvesicles and diagnosis
Microvesicles are generally larger (100–1000 nm in diameter)
than exosomes [4–6]. Microvesicles shed from the surface of
Y. Ishikawa et al. / Journal of Oral Biosciences 56 (2014) 110–114 111
stimulated cells are considered as speciﬁc structures distinct from
exosomes [42]. Microvesicles also participate in intracellular com-
munication [4], surface membrane trafﬁc, and the horizontal
transfer of protein and RNAs between neighboring cells [42]. This
horizontal transfer is important for the metabolism of target cells
[43].
Xiao et al. identiﬁed 63 proteins in salivary microvesicles by gel
electrophoresis with liquid chromatography-mass spectrometry
[44]. Salivary microvesicles have been shown to be potentially
useful in detecting breast cancer [45], as well as head and neck
cancer [38].
6. Salivary membrane transporters as biomarkers
Membrane transporters are divided into channels and carriers
[46]. Furthermore, carriers are divided into solute carriers (SLC)
[47] and ATP-binding cassette (ABC) transporters [48]. Channels,
including water channels (aquaporins) and ion channels, function
as selective pores that open in response to a chemical or electro-
physiological stimulus, allowing the movement of solutes down an
electrochemical gradient. Carriers translocate substrates across a
biological membrane.
Aquaporin (AQP) is an integral membrane protein with six
transmembrane domains. To date, 13 AQPs have been identiﬁed in
mammals [49]. AQP5 has been cloned from salivary glands [50].
Upon activation of M3-muscarinic acetylcholine receptors and α1-
adrenoceptors of parotid glands, AQP5 trafﬁcs rapidly to the apical
plasma membrane together with lipid rafts [51,52], resulting in the
release of AQP5 and lipid rafts into saliva [53]. As shown in Fig. 1,
human salivary AQP5 levels show diurnal rhythms with high levels
during waking hours.
During aging, salivary AQP5 levels decrease with salivary
volume [53]. In patients with diabetes mellitus or Sjögren's
syndrome, salivary AQP5 levels also decrease concomitantly with
salivary secretion [54]. Salivary AQP5 is therefore a useful biomar-
ker for diagnosis of xerostomia.
7. Conclusions
Membrane transporters in whole saliva, as well as salivary
exosomes and/or microvesicles, may be useful biomarkers for
disease diagnosis. For example, xerostomia can be diagnosed
based on salivary AQP5 levels. Salivary glands contain various
ion channels, such as chloride channels (CLC) [52], and may also be
useful as biomarkers for systemic or oral disease diagnosis.
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Fig. 1. Diurnal rhythm of AQP5 levels in healthy human saliva. Saliva was collected
for 1 min from healthy subjects, ranging in age from 20–39 years, at 4-h intervals
over a 24-h period, and was centrifuged at 1000g for 10 min (A). The resultant
supernatant was subjected to SDS-PAGE for western blotting with anti-human
AQP5 antibody. Concentration of AQP5 was measured in 50 μL of the resultant
supernatant by enzyme-linked immunosorbent assay (B) as described previously
[54]. *Value signiﬁcantly different from the value at 9 a.m. (po0.01).
Table 1
Characterization of salivary exosomes.
Saliva Isolation
strategy
Proteomic strategy Comments Ref.
Parotid saliva UC 1DE, LC–MS/MS  491 proteins identiﬁed in exosomes.
 Alix, AQP5, UBA1, VSP28, annexin, ATPase, and cytokeratins are present in exosomes.
[30]
Whole saliva GF 2DE, MALDI-TOF-MS
LC–MS/MS
 Exosome I and exosome II were identiﬁed.
 DPP IV, CD63, CD81, CD9, prominin-1 AQP5, and G-protein coupled receptor are present in both
types of exosome.
 Mucin-5B, Gi/Gs/Gt subunit beta-1, and annexins are present in exosome I.
 DPPIV, cystatins, IgG Fc binding protein, and CD26 are present in exosome II.
[40]
Whole saliva UC AFM  Exosome populations, exosome size, and inter-exosome are increased in oral cancer patient saliva [55]
Whole saliva UC Quantitative RT-PCR  MicroRNAs are concentrated in exosomes [56]
Whole saliva GF Small RNA genome  Small RNAs (miRNA, piRNA, snoRNA, and other small RNAs) are present in exosomes [57]
UC: ultracentrifugation; GF: gel ﬁltration; 1DE: 1D electrophoresis,
2DE: 2D electrophoresis; AFM: atomic force microscope;
LC–MS/MS: liquid chromatography–tandem mass spectrometry;
MALDI-TOF: matrix-assist-laser dissociation ionization-time of ﬂight,
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